Glaxosmithkline Biologicals Sa

Smithkline Beecham Biologicals S.a.

Smithkline Beecham Biologicals

Moncef Mohamed Slaoui

Joseph D Cohen

Nathalie Marie-Josephe Garcon-Johnson

Carlota Vinals Bassols

Nathalie Garcon

Jean-Paul H Prieels

Teresa Cabezon Silva

Pietro Pala

Christian Van Hoecke

Pierre Hauser

Pierre Desmons

Pierre Vandepapeliere

Pierre Voet

Nathalie Marie-Josephe Claude Garcon-Johnson

Myriam Francotte

Teresa Cabezon Sil Va

John Paul Prieels

Joseph Cohen

The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation.

Methods for one-dose intradermal delivery for non-live trivalent influenza vaccine

The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.

Process for the production of immunogenic compositions

The invention relates to the use of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation, in the manufacture of a one-dose influenza vaccine for intradermal delivery. In particular, the invention relates to the use of split influenza preparations wherein the vaccine comprises at least one non-ionic surfactant selected from the group consisting of the octyl-or nonylphenoxy polyoxyethanols (for example the commercially available Triton&#x2122; series), polyoxyethylene sorbitan esters (Tween&#x2122; series) and polyoxyethylene ethers or esters of general formula (I): HO(CHCHO)-A-R, wherein n is 1-50, A is a bond or &#x2014;C(O)&#x2014;, R is Calkyl or phenyl Calkyl; and combinations of two or more of these.

Non-live trivalent influenza vaccine for one-dose intradermal delivery

The present invention relates to novel MAGE3 polypeptides, including a fragment of MAGE3 fused to an immunological fusion partner, and compositions thereof.

MAGE3 polypeptides

Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a hepatitis B viral antigen, a VZV antigen, a HCMV antigen,antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

Composition

The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and &#x3b3; IFN responses.

Vaccine composition containing adjuvants

A method of administering a vaccine to females to prevent or treat infections associated with pathogens which cause sexually transmitted diseases is described. The vaccine comprises one or more antigens for the prevention or treatment of sexually transmitted diseases, for example an HSV glycoprotein D or an immunological fragment thereof, and an adjuvant, especially a TH-1 inducing adjuvant. The use of the vaccine components for the formulation of a vaccine composition for the prevention or treatment of sexually transmitted diseases in female subjects is also described.

Methods of treating human females susceptible to HSV infection

Novel herpes simplex (HSV) vaccine formulations are provided. These comprise HSV glycoprotein gD or immunological fragments in conjunction with 3 Deacylated monophosphoryl lipid A.

Growing community of inventors

Rixensart, Belgium

Moncef Mohamed Slaoui